Pasar al contenido principal

LOS RECEPTORES NUCLEARES Y SUS GENES DIANA EN LA REGULACION DE LA RESPUESTA INMUNITARIA/INFLAMATORIA Y PATOLOGIAS ASOCIADAS

SAF2017-89510-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development

  • Font-Díaz, Joan
  • Jiménez-Panizo, Alba
  • Caelles, Carme
  • Vivanco, María d. M.
  • Pérez, Paloma
  • Aranda, Ana
  • Estébanez-Perpiñá, Eva
  • Castrillo, Antonio
  • Ricote, M. Mercedes
  • Valledor, Annabel F.
Versión de autor del artículo, 93 páginas, 3 figuras 1 tabla, Nuclear receptors (NRs) are a superfamily of ligand-activated transcription factors that act as biological sensors and use a combination of mechanisms to modulate positively and negatively gene expression in a spatial and temporal manner. The highly orchestrated biological actions of several NRs influence the proliferation, differentiation, and apoptosis of many different cell types. Synthetic ligands for several NRs have been the focus of extensive drug discovery efforts for cancer intervention. This review summarizes the roles in tumour growth and metastasis of several relevant NR family members, namely androgen receptor (AR), estrogen receptor (ER), glucocorticoid receptor (GR), thyroid hormone receptor (TR), retinoic acid receptors (RARs), retinoid X receptors (RXRs), peroxisome proliferator-activated receptors (PPARs), and liver X receptors (LXRs). These studies are key to develop improved therapeutic agents based on novel modes of action with reduced side effects and overcoming resistance., This work was supported by grants from the Spanish Ministry of Economy and Competitivity (MINECO) to AFV and CC (SAF2017-89510- R), to AA (SAF2017-83289-R), to MV (SAF2017-84934-R), to PP (SAF2017-88046-R), to EE (BFU2017-86906-R), and to the NuRCaMeIn network (SAF2017-90604REDT); grants from the Spanish Ministry of Science, Innovation and Universities (MCNU) and Fondo Europeo de Desarrollo Regional (FEDER) to MR (RTI2018-095928-B100) and AC (PID2019-104284RB-I00/AEI/10.13039/501100011033); a grant from Instituto de Salud Carlos III to AA (CIBERONC CB/16/00228); grants from the Autonomous Community of Madrid to AA (B2017/BMD-3724) and MR (MOIR-B2017/BMD-3684); grants from Fundació La Marato ´ de TV3 to CC (201605-30), AFV (201605-31) and MR (201605-32); a grant from the Government of the Autonomous Community of Basque Country, Department of Industry, Tourism and Trade to MV (Elkartek, KK-2018/ 00054); and a grant from La Caixa to EEP (CaixaImpulse-CI-0018). JFD received a fellowship from the Spanish Ministry of Science, Innovation and Universities (FPI, PRE2018-085579). The CNIC is supported by the MCNU and the Pro CNIC Foundation and is a Severo Ochoa Centre of Excellence (SEV-2015-0505). CIC bioGUNE is a Severo Ochoa Centre of Excellence (SEV-2016-0644), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacologic activation of LXR alters the expression profile of tumor-associated macrophages and the abundance of regulatory T cells in the tumor microenvironment

  • Carbó, José María
  • León, Theresa E.
  • Font-Díaz, Joan
  • Rosa, Juan V. de la
  • Castrillo, Antonio
  • Picard, Felix R.
  • Staudenraus, Daniel
  • Huber, Magdalena
  • Cedó, Lídia
  • Escolà-Gil, Joan Carles
  • Campos, Lucía
  • Bakiri, Latifa
  • Wagner, Erwin F.
  • Caelles, Carme
  • Stratmann, Thomas
  • Ginderachter, Jo A. Van
  • Valledor, Annabel F.
Liver X receptors (LXR) are transcription factors from the nuclear receptor family that are activated by oxysterols and synthetic high-affinity agonists. In this study, we assessed the antitumor effects of synthetic LXR agonist TO901317 in a murine model of syngeneic Lewis Lung carcinoma. Treatment with TO901317 inhibited tumor growth in wild-type, but not in LXR-deficient mice, indicating that the antitumor effects of the agonist depends on functional LXR activity in host cells. Pharmacologic activation of the LXR pathway reduced the intratumoral abundance of regulatory T cells (Treg) and the expression of the Treg-attracting chemokine Ccl17 by MHCIIhigh tumor-associated macrophages (TAM). Moreover, gene expression profiling indicated a broad negative impact of the LXR agonist on other mechanisms used by TAM for the maintenance of an immunosuppressive environment. In studies exploring the macrophage response to GM-CSF or IL4, activated LXR repressed IRF4 expression, resulting in subsequent downregulation of IRF4-dependent genes including Ccl17. Taken together, this work reveals the combined actions of the LXR pathway in the control of TAM responses that contribute to the antitumoral effects of pharmacologic LXR activation. Moreover, these data provide new insights for the development of novel therapeutic options for the treatment of cancer., This work was supported by the following grants: Spanish Ministry of Economy and Competitivity (MINECO) grants SAF2017-89510-R and SAF2014-57856-P [to A.F. Valledor and C. Caelles; SAF2014-56819-R to A. Castrillo; SAF2017-90604-REDT and SAF2015-71878-REDT to the NuRCaMeIn network (to A.F. Valledor, C. Caelles, and A. Castrillo); Spanish Ministry of Science and Innovation (MICINN) grants SAF2011-23402 and SAF2010-14989 (to A.F. Valledor); Fundacio La Marato de TV3 grant 080930 (to A.F. Valledor); grants DFG HU 1824/5-1, 1824/7-1, and 1824/9-1 (to M. Huber); the European Cooperation in Science and Technology (COST) Action BM1404 Mye-EUNITER (http://www.mye-euniter. eu/; to A.F. Valledor, J.A. Van Ginderachter); and Instituto de Salud Carlos III and FEDER “Una manera de hacer Europa” grant FIS 16/00139 (to J.C. Escola-Gil). CIBERDEM is an Instituto de Salud Carlos III project. J.M. C received a fellowship from the University of Barcelona (APIF) and J. Font-Díaz received a fellowship from the Spanish Ministry of Science, Innovation and Universities (FPI, PRE2018-085579).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The multivalency of the glucocorticoid receptor ligand-binding domain explains its manifold physiological activities

  • Jiménez-Panizo, Alba
  • Alegre-Martí, Andrea
  • Tettey, Theophilus T.
  • Fettweis, Gregory
  • Abella, Montserrat
  • Antón, Rosa
  • Johnson, Thomas A.
  • Kim, Sohyoung
  • Schiltz, R. Louis
  • Núñez-Barrios, Israel
  • Font-Diaz, Joan
  • Caelles, Carme
  • Valledor, Annabel F.
  • Pérez, Paloma
  • Rojas Mendoza, Ana M.
  • Fernández-Recio, Juan
  • Presman, Diego M.
  • Hager, Gordon L.
  • Fuentes-Prior, Pablo
  • Estébanez-Perpiñá, Eva
20 páginas, 7 figuras, The glucocorticoid receptor (GR) is a ubiquitously expressed transcription factor that controls metabolic and homeostatic processes essential for life. Although numerous crystal structures of the GR ligand-binding domain (GR-LBD) have been reported, the functional oligomeric state of the full-length receptor, which is essential for its transcriptional activity, remains disputed. Here we present five new crystal structures of agonist-bound GR-LBD, along with a thorough analysis of previous structural work. We identify four distinct homodimerization interfaces on the GR-LBD surface, which can associate into 20 topologically different homodimers. Biologically relevant homodimers were identified by studying a battery of GR point mutants including crosslinking assays in solution, quantitative fluorescence microscopy in living cells, and transcriptomic analyses. Our results highlight the relevance of non-canonical dimerization modes for GR, especially of contacts made by loop L1-3 residues such as Tyr545. Our work illustrates the unique flexibility of GR's LBD and suggests different dimeric conformations within cells. In addition, we unveil pathophysiologically relevant quaternary assemblies of the receptor with important implications for glucocorticoid action and drug design, E.E.-P. thanks the generosity of the Gemma E. Carretero Fund; MINECO [BFU2017-86906-R, SAF2017-71878-REDT, SAF2015-71878-REDT to E.E.-P., RTI2018-101500-B-I00 to P.F.-P., RTI2018-096735-B-100 to A.R.M., PID2019-110167RB-I00 to J.F.-R., SAF2017-89510-R to A.V.F. and C.C.]; G.L.H thanks the NIH Intramural Research Program; D.M.P was supported by CONICET. Funding for open access charge: Spanish Ministry of Science (MINECO)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Endogenous LXR signaling controls pulmonary surfactant homeostasis and prevents lung inflammation

  • Hernández-Hernández, Irene
  • Rosa, Juan V. de la
  • Martín-Rodríguez, Patricia
  • Díaz-Sarmineto, Mercedes
  • Recio, Carlota
  • Guerra, Borja
  • Fernández-Pérez, Leandro
  • León, Theresa E.
  • Torres, Rosa
  • Font-Díaz, Joan
  • Roig, Ángela
  • Mora, Fernando de
  • Boscá, Lisardo
  • Díaz, Mario
  • Valledor, Annabel F.
  • Castrillo, Antonio
Lung type 2 pneumocytes (T2Ps) and alveolar macrophages (AMs) play crucial roles in the synthesis, recycling and catabolism of surfactant material, a lipid/protein fluid essential for respiratory function. The liver X receptors (LXR), LXRα and LXRβ, are transcription factors important for lipid metabolism and inflammation. While LXR activation exerts anti-inflammatory actions in lung injury caused by lipopolysaccharide (LPS) and other inflammatory stimuli, the full extent of the endogenous LXR transcriptional activity in pulmonary homeostasis is incompletely understood. Here, using mice lacking LXRα and LXRβ as experimental models, we describe how the loss of LXRs causes pulmonary lipidosis, pulmonary congestion, fibrosis and chronic inflammation due to defective de novo synthesis and recycling of surfactant material by T2Ps and defective phagocytosis and degradation of excess surfactant by AMs. LXR-deficient T2Ps display aberrant lamellar bodies and decreased expression of genes encoding for surfactant proteins and enzymes involved in cholesterol, fatty acids, and phospholipid metabolism. Moreover, LXR-deficient lungs accumulate foamy AMs with aberrant expression of cholesterol and phospholipid metabolism genes. Using a house dust mite aeroallergen-induced mouse model of asthma, we show that LXR-deficient mice exhibit a more pronounced airway reactivity to a methacholine challenge and greater pulmonary infiltration, indicating an altered physiology of LXR-deficient lungs. Moreover, pretreatment with LXR agonists ameliorated the airway reactivity in WT mice sensitized to house dust mite extracts, confirming that LXR plays an important role in lung physiology and suggesting that agonist pharmacology could be used to treat inflammatory lung diseases., This work was supported by grants from the Ministerio de Ciencia, Innovación y Fondo Europeo de Desarrollo Regional (FEDER), Agencia Estatal de Investigación grants PID2019-104284RB-I00, PID2022-137696OB-I00 funded by 10. 13039/501100011033 to AC and CT, grants PID2020-119875RB-I00 and SAF2017-89510-R to AFV and SAF2017-90604-REDT to the NuRCaMeIn network, grant PI18/01702 to FdM from the Instituto de Salud Carlos III and grant PROID2017010050 to CT from the Agencia Canaria de Investigación, Innovación y Sociedad de la Información (ACIISI). IHH and JFD received FPI predoctoral fellowships from the Spanish Ministerio de Ciencia, Innovación y Universidades (PRE2018-085579 to JFD and BES2009012191 to IHH)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Liver X Receptors and Inflammatory-Induced C/EBPβ Selectively Cooperate to Control CD38 Transcription

  • Glaria, Estibaliz
  • Rodríguez Martínez, Pol
  • Font-Díaz, Joan
  • Rosa, Juan V. de la
  • Castrillo, Antonio
  • Crawshaw, Dylan J.
  • Vidal Taboada, Jose Manuel
  • Saura, Josep
  • Matalonga, Jonathan
  • Chini, Eduardo N.
  • Caelles, Carme
  • Valledor, Annabel F.
[Introduction] Macrophages abundantly express liver X receptors (LXRs), which are ligand-dependent transcription factors and sensors of several cholesterol metabolites. In response to agonists, LXRs promote the expression of key lipid homeostasis regulators. Cross talk between LXRs and inflammatory signals exists in a cell type- and gene-specific manner. A common feature in the macrophage response to inflammatory mediators is the induction of CCAAT/enhancer-binding protein beta (C/EBPβ), a master transcriptional regulator and lineage-determining transcription factor in monocytes/macrophages., [Methods] Quantitative real-time PCR in control and C/EBPβ-deficient macrophages was used to explore the role of C/EBPβ in the cross talk between inflammatory mediators and the macrophage response to pharmacological LXR activation. The functional interaction between C/EBPβ and LXRs on selected genomic regions was further characterized by chromatin-immunoprecipitation (ChIP) and gene reporter studies., [Results] Whereas inflammatory signaling repressed several LXR-regulated genes involved in lipid metabolism, these effects were conserved after deletion of C/EBPβ. In contrast, inflammatory mediators and LXRs synergistically induced the expression of the multifunctional protein CD38 in a C/EBPβ-dependent manner. C/EBPβ and LXRs bound to several regions with enhancer activity upstream and within the mouse Cd38 gene and their functional cooperation in macrophages required intact binding sites for LXR and C/EBPβ., [Conclusion] This study reveals positive cross talk between C/EBPβ and LXRs during the macrophage inflammatory response, which selectively impacts CD38 expression., This work was supported by Grants SAF2017-89510-R and PID2020-119875RB-I00 to A.F.V. and C.C., PID2022-137696OB-I00 to A.C., and SAF2017-90604-REDT and SAF2015-71878-REDT to the NuRCaMeIn network, funded by MICIU/AEI/10.13039/501100011033 and by ERDF A way of making Europe; grants 201605.30 to A.F.V. and 201605.31 to C.C. funded by Fundació La Marató de TV3; grants PI14/302 to J.S., and PI19/0593 and PI23/0850 to J.M.V.T., funded by Instituto de Salud Carlos III and by ERDF/EU A way to make Europe; grant from Fundación Luzón (Programa de Ayudas para Proyectos de Investigación en ELA Unzué-Luzón 2024) to J.M.V.T.; grants 2021SGR01433 and 2021SGR01121 from AGAUR-Generalitat de Catalunya to A.F.V. and J.M.V.T., respectively; and the European Cooperation in Science and Technology (COST) Actions BM1404 Mye-EUNITER and CA20117 Mye-InfoBank. E.G. received a fellowship from the University of Barcelona (APIF). J.F.D. and J.M. received fellowships PRE2018-085579 and BES-2009-014828, respectively, funded by MICIU/AEI/10.13039/501100011033 and by FSE invests in your future., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nicotinamide Prevents Apolipoprotein B-Containing Lipoprotein Oxidation, Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Letelier, Nicole
  • Farré, Núria|||0000-0003-3110-6572
  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Nieto-Nicolau, Núria|||0000-0002-3527-0110
  • Rodríguez-Millán, Elisabeth
  • Santos, David|||0000-0003-1157-4969
  • Pallarès, Victor|||0000-0002-9851-0345
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Vázquez del Olmo, Tania
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Casaroli-Marano, Ricardo Pedro|||0000-0003-1812-9323
  • Valledor, Annabel F.|||0000-0003-4232-2633
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
The potential of nicotinamide (NAM) to prevent atherosclerosis has not yet been examined. This study investigated the effect of NAM supplementation on the development of atherosclerosis in a mouse model of the disease. The development of aortic atherosclerosis was significantly reduced (NAM low dose: 45%; NAM high dose: 55%) in NAM-treated, apolipoprotein (Apo)E-deficient mice challenged with a Western diet for 4 weeks. NAM administration significantly increased (1.8-fold) the plasma concentration of proatherogenic ApoB-containing lipoproteins in NAM high-dose (HD)-treated mice compared with untreated mice. However, isolated ApoB-containing lipoproteins from NAM HD mice were less prone to oxidation than those of untreated mice. This result was consistent with the decreased (1.5-fold) concentration of oxidized low-density lipoproteins in this group. Immunohistochemical staining of aortas from NAM-treated mice showed significantly increased levels of IL-10 (NAM low-dose (LD): 1.3-fold; NAM HD: 1.2-fold), concomitant with a significant decrease in the relative expression of TNFα (NAM LD: -44%; NAM HD: -57%). An improved anti-inflammatory pattern was reproduced in macrophages cultured in the presence of NAM. Thus, dietary NAM supplementation in ApoE-deficient mice prevented the development of atherosclerosis and improved protection against ApoB-containing lipoprotein oxidation and aortic inflammation.